Cargando…

Performance of [(18)F]flutemetamol amyloid imaging against the neuritic plaque component of CERAD and the current (2012) NIA-AA recommendations for the neuropathologic diagnosis of Alzheimer's disease

INTRODUCTION: Performance of the amyloid tracer [(18)F]flutemetamol was evaluated against three pathology standard of truth (SoT) measures including neuritic plaques (CERAD “original” and “modified” and the amyloid component of the 2012 NIA-AA guidelines). METHODS: After [(18)F]flutemetamol imaging,...

Descripción completa

Detalles Bibliográficos
Autores principales: Salloway, Stephen, Gamez, Jose E., Singh, Upinder, Sadowsky, Carl H., Villena, Teresa, Sabbagh, Marwan N., Beach, Thomas G., Duara, Ranjan, Fleisher, Adam S., Frey, Kirk A., Walker, Zuzana, Hunjan, Arvinder, Escovar, Yavir M., Agronin, Marc E., Ross, Joel, Bozoki, Andrea, Akinola, Mary, Shi, Jiong, Vandenberghe, Rik, Ikonomovic, Milos D., Sherwin, Paul F., Farrar, Gill, Smith, Adrian P.L., Buckley, Christopher J., Thal, Dietmar Rudolf, Zanette, Michelle, Curtis, Craig
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5536824/
https://www.ncbi.nlm.nih.gov/pubmed/28795133
http://dx.doi.org/10.1016/j.dadm.2017.06.001
_version_ 1783254084789207040
author Salloway, Stephen
Gamez, Jose E.
Singh, Upinder
Sadowsky, Carl H.
Villena, Teresa
Sabbagh, Marwan N.
Beach, Thomas G.
Duara, Ranjan
Fleisher, Adam S.
Frey, Kirk A.
Walker, Zuzana
Hunjan, Arvinder
Escovar, Yavir M.
Agronin, Marc E.
Ross, Joel
Bozoki, Andrea
Akinola, Mary
Shi, Jiong
Vandenberghe, Rik
Ikonomovic, Milos D.
Sherwin, Paul F.
Farrar, Gill
Smith, Adrian P.L.
Buckley, Christopher J.
Thal, Dietmar Rudolf
Zanette, Michelle
Curtis, Craig
author_facet Salloway, Stephen
Gamez, Jose E.
Singh, Upinder
Sadowsky, Carl H.
Villena, Teresa
Sabbagh, Marwan N.
Beach, Thomas G.
Duara, Ranjan
Fleisher, Adam S.
Frey, Kirk A.
Walker, Zuzana
Hunjan, Arvinder
Escovar, Yavir M.
Agronin, Marc E.
Ross, Joel
Bozoki, Andrea
Akinola, Mary
Shi, Jiong
Vandenberghe, Rik
Ikonomovic, Milos D.
Sherwin, Paul F.
Farrar, Gill
Smith, Adrian P.L.
Buckley, Christopher J.
Thal, Dietmar Rudolf
Zanette, Michelle
Curtis, Craig
author_sort Salloway, Stephen
collection PubMed
description INTRODUCTION: Performance of the amyloid tracer [(18)F]flutemetamol was evaluated against three pathology standard of truth (SoT) measures including neuritic plaques (CERAD “original” and “modified” and the amyloid component of the 2012 NIA-AA guidelines). METHODS: After [(18)F]flutemetamol imaging, 106 end-of-life patients who died underwent postmortem brain examination for amyloid plaque load. Blinded positron emission tomography scan interpretations by five independent electronically trained readers were compared with pathology measures. RESULTS: By SoT, sensitivity and specificity of majority image interpretations were, respectively, 91.9% and 87.5% with “original CERAD,” 90.8% and 90.0% with “modified CERAD,” and 85.7% and 100% with the 2012 NIA-AA criteria. DISCUSSION: The high accuracy of either CERAD criteria suggests that [(18)F]flutemetamol predominantly reflects neuritic amyloid plaque density. However, the use of CERAD criteria as the SoT can result in some false-positive results because of the presence of diffuse plaques, which are accounted for when the positron emission tomography read is compared with the 2012 NIA-AA criteria.
format Online
Article
Text
id pubmed-5536824
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-55368242017-08-09 Performance of [(18)F]flutemetamol amyloid imaging against the neuritic plaque component of CERAD and the current (2012) NIA-AA recommendations for the neuropathologic diagnosis of Alzheimer's disease Salloway, Stephen Gamez, Jose E. Singh, Upinder Sadowsky, Carl H. Villena, Teresa Sabbagh, Marwan N. Beach, Thomas G. Duara, Ranjan Fleisher, Adam S. Frey, Kirk A. Walker, Zuzana Hunjan, Arvinder Escovar, Yavir M. Agronin, Marc E. Ross, Joel Bozoki, Andrea Akinola, Mary Shi, Jiong Vandenberghe, Rik Ikonomovic, Milos D. Sherwin, Paul F. Farrar, Gill Smith, Adrian P.L. Buckley, Christopher J. Thal, Dietmar Rudolf Zanette, Michelle Curtis, Craig Alzheimers Dement (Amst) Neuroimaging INTRODUCTION: Performance of the amyloid tracer [(18)F]flutemetamol was evaluated against three pathology standard of truth (SoT) measures including neuritic plaques (CERAD “original” and “modified” and the amyloid component of the 2012 NIA-AA guidelines). METHODS: After [(18)F]flutemetamol imaging, 106 end-of-life patients who died underwent postmortem brain examination for amyloid plaque load. Blinded positron emission tomography scan interpretations by five independent electronically trained readers were compared with pathology measures. RESULTS: By SoT, sensitivity and specificity of majority image interpretations were, respectively, 91.9% and 87.5% with “original CERAD,” 90.8% and 90.0% with “modified CERAD,” and 85.7% and 100% with the 2012 NIA-AA criteria. DISCUSSION: The high accuracy of either CERAD criteria suggests that [(18)F]flutemetamol predominantly reflects neuritic amyloid plaque density. However, the use of CERAD criteria as the SoT can result in some false-positive results because of the presence of diffuse plaques, which are accounted for when the positron emission tomography read is compared with the 2012 NIA-AA criteria. Elsevier 2017-07-01 /pmc/articles/PMC5536824/ /pubmed/28795133 http://dx.doi.org/10.1016/j.dadm.2017.06.001 Text en © 2017 GE Healthcare http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Neuroimaging
Salloway, Stephen
Gamez, Jose E.
Singh, Upinder
Sadowsky, Carl H.
Villena, Teresa
Sabbagh, Marwan N.
Beach, Thomas G.
Duara, Ranjan
Fleisher, Adam S.
Frey, Kirk A.
Walker, Zuzana
Hunjan, Arvinder
Escovar, Yavir M.
Agronin, Marc E.
Ross, Joel
Bozoki, Andrea
Akinola, Mary
Shi, Jiong
Vandenberghe, Rik
Ikonomovic, Milos D.
Sherwin, Paul F.
Farrar, Gill
Smith, Adrian P.L.
Buckley, Christopher J.
Thal, Dietmar Rudolf
Zanette, Michelle
Curtis, Craig
Performance of [(18)F]flutemetamol amyloid imaging against the neuritic plaque component of CERAD and the current (2012) NIA-AA recommendations for the neuropathologic diagnosis of Alzheimer's disease
title Performance of [(18)F]flutemetamol amyloid imaging against the neuritic plaque component of CERAD and the current (2012) NIA-AA recommendations for the neuropathologic diagnosis of Alzheimer's disease
title_full Performance of [(18)F]flutemetamol amyloid imaging against the neuritic plaque component of CERAD and the current (2012) NIA-AA recommendations for the neuropathologic diagnosis of Alzheimer's disease
title_fullStr Performance of [(18)F]flutemetamol amyloid imaging against the neuritic plaque component of CERAD and the current (2012) NIA-AA recommendations for the neuropathologic diagnosis of Alzheimer's disease
title_full_unstemmed Performance of [(18)F]flutemetamol amyloid imaging against the neuritic plaque component of CERAD and the current (2012) NIA-AA recommendations for the neuropathologic diagnosis of Alzheimer's disease
title_short Performance of [(18)F]flutemetamol amyloid imaging against the neuritic plaque component of CERAD and the current (2012) NIA-AA recommendations for the neuropathologic diagnosis of Alzheimer's disease
title_sort performance of [(18)f]flutemetamol amyloid imaging against the neuritic plaque component of cerad and the current (2012) nia-aa recommendations for the neuropathologic diagnosis of alzheimer's disease
topic Neuroimaging
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5536824/
https://www.ncbi.nlm.nih.gov/pubmed/28795133
http://dx.doi.org/10.1016/j.dadm.2017.06.001
work_keys_str_mv AT sallowaystephen performanceof18fflutemetamolamyloidimagingagainsttheneuriticplaquecomponentofceradandthecurrent2012niaaarecommendationsfortheneuropathologicdiagnosisofalzheimersdisease
AT gamezjosee performanceof18fflutemetamolamyloidimagingagainsttheneuriticplaquecomponentofceradandthecurrent2012niaaarecommendationsfortheneuropathologicdiagnosisofalzheimersdisease
AT singhupinder performanceof18fflutemetamolamyloidimagingagainsttheneuriticplaquecomponentofceradandthecurrent2012niaaarecommendationsfortheneuropathologicdiagnosisofalzheimersdisease
AT sadowskycarlh performanceof18fflutemetamolamyloidimagingagainsttheneuriticplaquecomponentofceradandthecurrent2012niaaarecommendationsfortheneuropathologicdiagnosisofalzheimersdisease
AT villenateresa performanceof18fflutemetamolamyloidimagingagainsttheneuriticplaquecomponentofceradandthecurrent2012niaaarecommendationsfortheneuropathologicdiagnosisofalzheimersdisease
AT sabbaghmarwann performanceof18fflutemetamolamyloidimagingagainsttheneuriticplaquecomponentofceradandthecurrent2012niaaarecommendationsfortheneuropathologicdiagnosisofalzheimersdisease
AT beachthomasg performanceof18fflutemetamolamyloidimagingagainsttheneuriticplaquecomponentofceradandthecurrent2012niaaarecommendationsfortheneuropathologicdiagnosisofalzheimersdisease
AT duararanjan performanceof18fflutemetamolamyloidimagingagainsttheneuriticplaquecomponentofceradandthecurrent2012niaaarecommendationsfortheneuropathologicdiagnosisofalzheimersdisease
AT fleisheradams performanceof18fflutemetamolamyloidimagingagainsttheneuriticplaquecomponentofceradandthecurrent2012niaaarecommendationsfortheneuropathologicdiagnosisofalzheimersdisease
AT freykirka performanceof18fflutemetamolamyloidimagingagainsttheneuriticplaquecomponentofceradandthecurrent2012niaaarecommendationsfortheneuropathologicdiagnosisofalzheimersdisease
AT walkerzuzana performanceof18fflutemetamolamyloidimagingagainsttheneuriticplaquecomponentofceradandthecurrent2012niaaarecommendationsfortheneuropathologicdiagnosisofalzheimersdisease
AT hunjanarvinder performanceof18fflutemetamolamyloidimagingagainsttheneuriticplaquecomponentofceradandthecurrent2012niaaarecommendationsfortheneuropathologicdiagnosisofalzheimersdisease
AT escovaryavirm performanceof18fflutemetamolamyloidimagingagainsttheneuriticplaquecomponentofceradandthecurrent2012niaaarecommendationsfortheneuropathologicdiagnosisofalzheimersdisease
AT agroninmarce performanceof18fflutemetamolamyloidimagingagainsttheneuriticplaquecomponentofceradandthecurrent2012niaaarecommendationsfortheneuropathologicdiagnosisofalzheimersdisease
AT rossjoel performanceof18fflutemetamolamyloidimagingagainsttheneuriticplaquecomponentofceradandthecurrent2012niaaarecommendationsfortheneuropathologicdiagnosisofalzheimersdisease
AT bozokiandrea performanceof18fflutemetamolamyloidimagingagainsttheneuriticplaquecomponentofceradandthecurrent2012niaaarecommendationsfortheneuropathologicdiagnosisofalzheimersdisease
AT akinolamary performanceof18fflutemetamolamyloidimagingagainsttheneuriticplaquecomponentofceradandthecurrent2012niaaarecommendationsfortheneuropathologicdiagnosisofalzheimersdisease
AT shijiong performanceof18fflutemetamolamyloidimagingagainsttheneuriticplaquecomponentofceradandthecurrent2012niaaarecommendationsfortheneuropathologicdiagnosisofalzheimersdisease
AT vandenbergherik performanceof18fflutemetamolamyloidimagingagainsttheneuriticplaquecomponentofceradandthecurrent2012niaaarecommendationsfortheneuropathologicdiagnosisofalzheimersdisease
AT ikonomovicmilosd performanceof18fflutemetamolamyloidimagingagainsttheneuriticplaquecomponentofceradandthecurrent2012niaaarecommendationsfortheneuropathologicdiagnosisofalzheimersdisease
AT sherwinpaulf performanceof18fflutemetamolamyloidimagingagainsttheneuriticplaquecomponentofceradandthecurrent2012niaaarecommendationsfortheneuropathologicdiagnosisofalzheimersdisease
AT farrargill performanceof18fflutemetamolamyloidimagingagainsttheneuriticplaquecomponentofceradandthecurrent2012niaaarecommendationsfortheneuropathologicdiagnosisofalzheimersdisease
AT smithadrianpl performanceof18fflutemetamolamyloidimagingagainsttheneuriticplaquecomponentofceradandthecurrent2012niaaarecommendationsfortheneuropathologicdiagnosisofalzheimersdisease
AT buckleychristopherj performanceof18fflutemetamolamyloidimagingagainsttheneuriticplaquecomponentofceradandthecurrent2012niaaarecommendationsfortheneuropathologicdiagnosisofalzheimersdisease
AT thaldietmarrudolf performanceof18fflutemetamolamyloidimagingagainsttheneuriticplaquecomponentofceradandthecurrent2012niaaarecommendationsfortheneuropathologicdiagnosisofalzheimersdisease
AT zanettemichelle performanceof18fflutemetamolamyloidimagingagainsttheneuriticplaquecomponentofceradandthecurrent2012niaaarecommendationsfortheneuropathologicdiagnosisofalzheimersdisease
AT curtiscraig performanceof18fflutemetamolamyloidimagingagainsttheneuriticplaquecomponentofceradandthecurrent2012niaaarecommendationsfortheneuropathologicdiagnosisofalzheimersdisease